HEAL
HLA-homozygous iPSC-cardiomyocyteE Aggregate manufacturing technologies for allogenic cell therapy to the heart
The European Union Research & Innovation Action is funding the HEAL research project, which involves ten partners from all over Europe and Israel, with more than six million euros, of which the Medical School Hannover (MHH) is the coordinating institution.
One goal of the network is establishing new tools and expertise for accelerating the development of advanced human induced pluripotent stem cell (iPSC)-based therapies. The project also aims for overcoming scientific, regulatory and in particular safety hurdles, necessary to initiate a first-in-man (FIM) clinical trial for the therapeutic administration of allogeneic, human leukocyte antigen (HLA)-homozygous iPSC-cardiomyocyte aggregates, for improving the function of damaged hearts.
Consortium Partner
The consortium is composed of world leading-expertise of academic, clinical and industrial partners in the field of iPSC technology, bioprocessing, genomic engineering, analysis and safety, immunology and clinical translation.
Objectives of the project
The overarching goal of the network is to establish new tools, technologies and expertise for accelerating the development of advanced human induced pluripotent stem cell (iPSC)-based therapies.
Publications
Please have a look at the publications related to the HEAL project.
Partner Portal
